Poor aqueous solubility of many antihypertensive drugs limits their oral bioavailability and optimal therapeutic response. Olmesartan medoxomil, a widely used angiotensin-II receptor blocker, belongs to BCS Class-II with high permeability but low solubility, causing variable absorption and delayed action. Therefore, improving its solubility and dissolution is essential for better clinical performance. This study aims to design, optimize and evaluate amorphous solid dispersion (ASD) loaded nanoformulations of olmesartan medoxomil to significantly improve its solubility and in vitro drug release. For this purpose, at first olmesartan will be converted into amorphous solid dispersions using hydrophilic polymeric carrier such as poloxamer 188 via solvent evaporation method. These ASDs will then be incorporated into nano based delivery systems such as nanosuspensions to further enhance wetting and dissolution kinetics. After that, a statistical design of experiments (DoE) approach will be employed to optimize the drug-to-polymer ratio with key responses including particle size and polydispersity index. The optimized nanoformulation will be extensively characterized using DSC and XRD for confirmation of amorphous conversion, FTIR for drug-polymer compatibility, dynamic light scattering for particle size and zeta potential, SEM for surface morphology and in vitro dissolution studies. The final formulations will then be compared with the market product to quantify improvement in dissolution efficiency and solubility enhancement. This innovative nano enabled amorphous drug delivery approach is expected to produce a physically stable high performance oral formulation of olmesartan medoxomil with superior dissolution and potentially improved bioavailability. The findings will contribute significantly to the development of advanced drug delivery strategies for poorly soluble cardiovascular drugs.